Helsinn Group, based in Lugano, Switzerland, and MEI Pharma, with headquarters in San Diego, announced they were discontinuing their Phase III trial of pracinostat with azacytidine in acute myeloid leukemia (AML).
Researchers tested a new drug combo that shows promise for the treatment of the childhood brain cancers diffuse midline gliomas.
